The "Make America Healthy Again" movement notched a big win on pesticide regulation during Thursday's debate on a House farm bill, only to see the White House pull the nomination of a favored influencer for surgeon general hours later.
Why it matters: The events showed how the movement continues to have clout on matters related to the food supply, but can be a political liability when it comes to vaccines and other public health matters.
President Trump announced a new nominee for surgeon general Thursday, picking Nicole Saphier of the Memorial Sloan Kettering Cancer Center, a former Fox News medical contributor, for the top health job.
Why it matters: Trump said he's dropping his previous nominee, Casey Means, a nutrition influencer and ally of Health Secretary Robert F. Kennedy Jr., who struggled to win enough Republican support to be confirmed by the Senate.
A new fight over health price transparency is playing out in an unusual copyright lawsuit over a hospital billing manual.
Why it matters: Hospitals have been required since 2021 to post prices for items and services in a consumer-friendly way, but patient advocates say the system is still opaque.
Here is the most baffling paradox of 2026: Most Americans agree on most things most of the time — and yet, our feeds and screens scream civil war.
Our eyes and our front porches tell a different story.
Why it matters: Three events this week captured beautifully my core belief: The vast majority of Americans are decent, hardworking, neighbor-helping, kid-raising people who don't pop off online.
The Food and Drug Administration on Tuesday kicked off an effort to use AI and other data science tools to monitor clinical trials in real time and cut down review times for new drugs.
Why it matters: Agency leaders portrayed the move as a major step toward keeping U.S. biomedical research competitive against countries like China.
Supreme Court justices on Wednesday will hear arguments in a patent case that could change the way generic drug companies market and label copycat products.
Why it matters: At the heart of the case is whether efforts to lower health costs through generic competition are undercutting patent protections that brand-name drugmakers say are essential for innovation.
